Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial

Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The page's revision changed from v3.5.2 to v3.5.3, indicating a small backend update. It reflects an internal version bump rather than a change to the displayed study information.
    Difference
    0.0%
    Check dated 2026-04-27T20:14:55.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Page revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-20T16:20:17.000Z thumbnail image
  4. Check
    49 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-22T22:09:41.000Z thumbnail image
  5. Check
    63 days ago
    Change Detected
    Summary
    Revision: v3.4.3 implemented. No visible changes to study data, eligibility criteria, or study details.
    Difference
    0.0%
    Check dated 2026-03-08T13:36:57.000Z thumbnail image
  6. Check
    85 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.1 to v3.4.2; no study data or page functionality appears to be altered.
    Difference
    0.0%
    Check dated 2026-02-14T22:45:14.000Z thumbnail image
  7. Check
    92 days ago
    Change Detected
    Summary
    Added Primary peritoneal carcinoma to the conditions, introduced a Resources section with the Genetic and Rare Diseases Information Center, and updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.2%
    Check dated 2026-02-07T17:13:19.000Z thumbnail image

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.